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ABSTRACT
Background. Ceratonia siliqua pods (carob) have been nominated to control the high
blood glucose of diabetics. In Yemen, however, its antihyperglycemic activity has
not been yet assessed. Thus, this study evaluated the in vitro inhibitory effect of the
methanolic extract of carob pods against α-amylase and α-glucosidase and the in vivo
glycemic effect of such extract in streptozotocin-nicotinamide induced diabetic rats.
Methods. 2,2-diphenyl-1-picrylhydrazyl (DPPH) and Ferric reducing antioxidant
power assay (FRAP) were applied to evaluate the antioxidant activity of carob. In vitro
cytotoxicity of carobwas conducted on human hepatocytes (WRL68) and rat pancreatic
β-cells (RIN-5F). Acute oral toxicity of carob was conducted on a total of 18 male and
18 female Sprague-Dawley (SD) rats, which were subdivided into three groups (n= 6),
namely: high and low dose carob-treated (CS5000 and CS2000, respectively) as well as
the normal control (NC) receiving a single oral dose of 5,000 mg kg−1 carob, 2,000 mg
kg−1 carob and 5mLkg−1 distilledwater for 14 days, respectively. Alkaline phosphatase,
aspartate aminotransferase, alanine aminotransferase, total bilirubin, creatinine and
urea were assessed. Livers and kidneys were harvested for histopathology. In vitro
inhibitory effect against α-amylase and α-glucosidase was evaluated. In vivo glycemic
activity was conducted on 24 male SD rats which were previously intraperitoneally
injected with 55 mg kg−1 streptozotocin (STZ) followed by 210 mg kg−1 nicotinamide
to induce type 2 diabetes mellitus. An extra non-injected group (n= 6) was added
as a normal control (NC). The injected-rats were divided into four groups (n= 6),
namely: diabetic control (D0), 5 mg kg−1 glibenclamide-treated diabetic (GD), 500
mg kg−1 carob-treated diabetic (CS500) and 1,000 mg kg−1 carob-treated diabetic
(CS1000). All groups received a single oral daily dose of their treatment for 4 weeks.
Body weight, fasting blood glucose (FBG), oral glucose tolerance test, biochemistry,
insulin and hemostatic model assessment were assessed. Pancreases was harvested for
histopathology.
Results. Carob demonstrated a FRAP value of 3191.67 ± 54.34 µmoL Fe++ and IC50
of DPPH of 11.23 ± 0.47 µg mL−1. In vitro, carob was non-toxic on hepatocytes and
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pancreatic β-cells. In acute oral toxicity, liver and kidney functions and their histological
sections showed no abnormalities. Carob exerted an in vitro inhibitory effect against
α-amylase and α-glucosidase with IC50 of 92.99 ± 0.22 and 97.13 ± 4.11 µg mL−1,
respectively. In diabetic induced rats, FBG of CS1000 was significantly less than diabetic
control. Histological pancreatic sections of CS1000 showed less destruction of β-cells
than CS500 and diabetic control.
Conclusion. Carob pod did not cause acute systemic toxicity and showed in vitro
antioxidant effects. On the other hand, inhibiting α-amylase and α-glucosidase was
evident. Interestingly, a high dose of carob exhibits an in vivo antihyperglycemic activity
andwarrants further in-depth study to identify the potential carob extract composition.
Subjects Diabetes and Endocrinology, Pharmacology
Keywords Carob, Ceratonia siliqua, Type 2 Diabetes Mellitus, α-amylase, α-glucosidase, Acute
oral toxicity, Cytotoxicity, HOMA-IR
INTRODUCTION
Diabetes mellitus (DM) is a widespread metabolic disorder that is estimated to affect 640
million people by 2040 (International Diabetes Federation, 2016). DM occurs owing to a
defect in either insulin secretion, insulin action, or both leading to an increase in blood glu-
cose (Gamboa-Gómez et al., 2017). Accordingly, DM is classified into either type 1 diabetes
mellitus (T1DM) which is insulin dependent or type 2 diabetes mellitus (T2DM) which is
non-insulin dependent (WHO, 2016). However, T2DM is the most common type of DM
constituting 90–95% of all cases of DM worldwide (Ahmed et al., 2016; Tripathi, 2013).
T2DM is mainly managed with oral hypoglycemic agents. However, due to the potential
side effects of those agents, World Health Organization (WHO) recommends using
alternative medicines (e.g., natural products) (Abdel-Sattar et al., 2013) as a second choice
(Saghir et al., 2016). As a matter of fact, more than 1,200 species of medicinal plants
could be used as an antidiabetic (Abdel-Sattar et al., 2013; Alarcon-Aguilar et al., 2002;
Hernandez-Galicia et al., 2002).
Carob (Ceratonia siliqua L) is an evergreen plant (Roseiro et al., 2013), which was
reported as a native plant to Yemen (Battle & Tous, 1997). Traditionally, C. Siliqua (carob)
is used as an antitussive, antidiarrheal and a diuretic (Baytop, 1984; Gulay et al., 2012;
Merzouki et al., 1997). However, C. Siliqua pods (Carob) were reported to exert several
pharmacological properties such as antioxidant, anti-ulcer and anti-inflammatory (Kivcak,
Mert & Ozturk, 2002; Rtibi et al., 2015a; Rtibi et al., 2017a; Rtibi et al., 2016).
In folk Yemeni medicine, diabetics claim that carob pods can reduce their elevated blood
sugar. However, no study has been conducted to explore the glycemic effect of the Yemeni
cultivar of carob pods. Consequently, this study sought to evaluate the glycemic and the
antioxidant activities of the methanolic extract of carob in streptozotocin-nicotinamide
induced diabetic rat model.
Qasem et al. (2018), PeerJ, DOI 10.7717/peerj.4788 2/27
MATERIALS AND METHODS
Materials and chemicals
Streptozotocin (Merck Millipore, Temecula, CA, USA), nicotinamide, sodium citrate
monohydrate, phosphate-buffered saline (PBS) and glucose anhydrous (Sigma-Aldrich, St.
Louis, MO, USA). Citric acid (Merck, Kenilworth, NJ, USA), glibenclamide (Sigma-
Aldrich, USA), formaldehyde (HmbG chemicals, Hamburg, Germany), one-touch
glucometer (Accu-Chek Performa, Roche, Mannheim, Germany). Rat Insulin ELISA
Kit (ER1113, Wuhan Fine Biological Technology Co., Ltd., China). 2,4,6-Tri (2- pyridyl)-
s-triazine, Folin-Ciocalteu reagent and ferric chloride (Sigma-Aldrich, USA). Cellulose
extraction thimble (Tokyo Roshi Kaisha, Ltd, Tokyo, Japan), ferrous sulphate heptahydrate
(Essex, UK). Amylase and glucosidase enzymes, 3, 5-dinitrosalicylic acid (DNSA) and 4-
Nitrophenyl (3-D-glucopyranoside (P-NPG) substrate, monobasic potassium phosphate
and potassium tartrate tetrahydrate (Sigma-Aldrich, USA),α-acarbose 95% (Acros organic,
USA). Potato starch (Sigma-Aldrich, USA).
Collection of plant material
Totally, two kilograms of unripe pods of carob were collected from Bani Yousef region,
70 km from Taiz governorate, Yemen. The pods were collected at 8 am, 15th May 2014.
The shoots were wrapped in aluminum foil sheets and put in ice-filled box to isolate it from
sunlight and external temperature. The unripe carob samples were transported directly to
the Laboratory of Pharmacognosy Department, Faculty of Pharmacy, Sana’a University,
Yemen. The plant was verified and authenticated by a taxonomist and given a voucher
specimen No. (CSL/2014/8/1), which was deposited at the Laboratory of Pharmacognosy,
Faculty of Pharmacy, Sana’a University, Yemen.
Extraction
The unripe carob pods were washed with purified water to eliminate debris and dried with
a fan. Then, the pods were chopped to small pieces and left to dry at room temperature
(28.0±2 ◦C) for three weeks. Next, chopped pieces were ground with a grinder to get
fine powder at department of Pharmacy, Faculty of Medicine, University of Malaya. One
kilogram of carob powder was extracted using Soxhlet method as previously described with
some modification (Jadhav et al., 2009). Extraction process was performed by methanol
using Soxhlet extractor under 50 ◦C. Filter paper (Whatman No. 1) was used to filter the
liquid extract. Rotavapor evaporator was used to separate the solutes from the solvents at
40 ◦C and the filtrate was allowed to dry in dark place. Finally, the dried filtered extract
was kept under −20 ◦C for later work.
In vivo and in vitro experimental model design of study
Fig. 1 Flow chart of the experimental design
Quantification of total phenolic and flavonoid content
Total phenolic content (TPC) of the methanolic extract of carob was determined using
Folin-Ciocalteu assay (Chan et al., 2009). Gallic acid was used as a reference. Totally, 20 µL
of the extract and gallic acid (1 mg mL−1) were pipetted into 96-well microplate followed
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Figure 1 In vivo and in vitro experimental model design of study. The flow chart of the experimental
design.
Full-size DOI: 10.7717/peerj.4788/fig-1
by addition of 50 µL of 10% Folin-Ciocalteu reagent to be incubated for 3.0 min. Then
100 µL of sodium carbonate (10%) was added followed by incubation for one hour.
The absorbance was measured at 765 nm spectrophotometrically (Infinite M 200; Tecan,
Männedorf, Switzerland). The phenolic content was represented as mg of gallic acid
equivalent/g extract.
Total flavonoid content (TFC) was estimated using AlCl3 method (Nabavi et al., 2008)
in which 10 µL of the extract and quercetin were transferred into 96-well plate, followed
by addition of 60 µL of DMSO. Then, 10 µL of 10% (w/v) aluminium chloride, 10 µL of
1 M potassium acetate and 120 µL of deionized water were added to the mixture, which
was incubated for 30 min at room temperature. Serial dilutions of quercetin (500–31.25
µg mL−1) were prepared to generate the calibration curve. The absorbance was measured
at 415 nm spectrophotometrically (Infinite M 200; Tecan, Switzerland). The flavonoid
content was presented as mg quercetin equivalent/g extract.
Evaluation of antioxidant properties of carob methanolic extract
Radical-scavenging activity of carob against free radicals of DPPH
Radical scavenging activity of the methanolic extract of carob was determined using
the stable free radical 2,2-diphenyl-1-picrylhydrazyl (DPPH•) with slight modifications
(Alshawsh et al., 2012). Briefly, 1.2 mg of DPPH was thawed out in 30 mL of DMSO to
prepare 100 µMDPPH reagent solution. Stock sample (1.0 mg/1.0 mLDMSO) was diluted.
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Serial dilutions; 500, 250, 125, 62.50, 31.25, 15.62 and 7.18 µg mL−1 of stock sample were
prepared. Totally, 25 µL of sample and 150 µL of DPPH solution were transferred into
96-wells plate. Next, the mixture was incubated in a dark place at room temperature
for 25 min. The absorption was measured spectrophotometrically (Infinite M 200 Tecan,
Switzerland) at 517 nm. Quercetin was used as a positive control. The amount of the extract
was replaced by DMSO in case of negative control. Percentage inhibition was obtained
using the following equation:
%Inhibition= [(Ac−As)/Ac]∗100.
where Ac is the absorbance of negative control, As is the absorbance of test sample.
The concentration of the methanolic carob extract that was able to inhibit 50% of the
free radicals of DPPH (IC50) was obtained from the calibration curve of sample and positive
control using a non-linear regression analysis and the results were expressed as an IC50
value ± SD. All determinations were conducted in triplicate to evaluate the IC50.
Ferric reducing antioxidant power assay (FRAP)
Measuring of ferric reducing antioxidant activity of the methanolic extract was performed
according to (Benzie & Strain, 1996). Working FRAP reagent was prepared through mixing
300 mM acetate buffer (pH 3.6), 10 mM 2,4,6-tripyridyl-s-triazine (TPTZ) in 40 mMHCL,
and 20mM ferric chloride (FeCl3.6H2O). Calibration curve was plotted using FeSO4 ·7H2O
serial concentrations between 100–1,000mgmL−1. Freshly prepared FRAPworking reagent
was warmed at 37 ◦C for 5 min, then 30 µL of the extract, Trolox and quercetin (1.0 mg
dissolved in 1.0 mL DMSO) were transferred into 96-well microplate and mixed with
300 µL of FRAP reagent. Then, absorbance was measured at 593 nm against the blank
(DMSO). The values were represented as µmoles of ferrous sulphate equivalent/mg extract.
In vitro inhibitory effect of carob against α-amylase and
α-glucosidase
The α-amylase inhibition capacity of the extract was determined according to Loizzo et
al. (2007). In brief, 20 µL of each test sample (1 mg mL−1extract) dissolved in DMSO or
standard Acarbose 95% (Acros Organic, Bridgewater, NJ, USA) and 50 µL 2U mL−1 of
α-amylase enzyme (Porcine Pancreas Amylase; 2 mg/10 mL; 10 Units/mg; Sigma-Aldrich,
USA) dissolved in cold deionized water were added into each well. After incubation for 10
min at 28 ◦C, 100µL of starch solution (0.5%w/v (Sigma-Aldrich,USA) prepared bymixing
250 mg potato starch in previously prepared 50 mL phosphate buffer pH 6.9 prepared by
mixing 20 mM monobasic sodium phosphate and 6.7 mM of sodium chloride and heated
at 60 ◦C for 15 min) was added to the reacting mixture. Thereafter, the reaction mixture
was re-incubated for 10 min at 28 ◦C and 100 µL of colorimetric DNSA reagent 96 mM
(Prepared by mixing 12 g of sodium potassium tartrate tetrahydrate in 8 mL of 2 M NaOH
and 0.5 mg 3,5-dinitrosalicylic acid solution) was added with mixing the contents well. The
reaction was terminated by incubating the mixture in a water bath 86 ◦C for 15 min and
later was cooled to room temperature. The blank was conducted in a similar method, with
the replaced α-amylase enzyme by deionized water. All the reagents involved the α-amylase
Qasem et al. (2018), PeerJ, DOI 10.7717/peerj.4788 5/27
enzyme with the exception of the test extracts was pointed as a reference sample. The
absorbance of reaction was measured by using UV-Visible spectrophotometry (Infinite M
200 Tecan, Switzerland) at 540 nm and the α-amylase inhibitory activity was expressed
as percentage inhibition. The assay was carried out in 96-well microplates (Solid clear
F-bottom, Greiner Bio One, Austria). The percentage of inhibition was obtained using the
following formula: % inhibition= [A reference–(A sample – A blank)/A reference)]×100.
Regarding α-glucosidase inhibitory activity of carob methanolic extract, it was assessed
spectrophotometrically according to Oboh et al. (2012) with few modifications. Briefly,
100 µL phosphate buffer solution of 2.5 U mL−1 α-glucosidase enzyme (Saccharomyces
cerevisiae; 2.5 mg 10 mL−1; 10 U mg−1; Sigma-Aldrich. St Louis, USA) and 50 µL of each
test sample solution (1 mg mL−1extract) dissolved in 30% DMSO were added in each well
and incubated at 25 ◦C for 10 min. Then, 50 µL of 4-Nitrophenyl (3-D-glucopyranoside
(P-NPG) substrate solution (5 mM of P-NPG (Sigma-Aldrich, St Louis, USA) 7.53 mg/5mL
dissolved in pH 6.9 phosphate buffer which prepared by mixing with 100 mM monobasic
potassium phosphate); was added to the reacting mixture and re-incubated for 5 min at
25 ◦C. Thereafter, 80 µL of 0.1M sodium carbonate solution was added to terminate the
catalytic reaction. Acarbose 95% (Acros Organic, USA) dissolved in 30% DMSO was used
as a positive control. The reference sample contained the same reaction mixture except the
same amount of test sample solution and positive control that were replaced by phosphate
buffer solution. The blank was included all reagents and test samples with the exception
of α-glucosidase enzyme. All measurements were performed in triplicate. The absorbance
of the reaction was recorded on UV-Visible spectrophotometry (Infinite M 200; Tecan,
Switzerland) at 405 nm. The assay was carried out in 96-well microplates (Solid clear
F-bottom, Greiner Bio One, Austria). The inhibitory rate of samples on α-glucosidase
enzyme was obtained using the following formula: % inhibition = [A reference – (A
sample – A blank)/A reference)] ×100.
In vitro cytotoxicity of the methanolic extract of carob
Cell culture
RIN-5F (rat pancreatic β-cell line) andWRL 68 (human hepatic cell line) (ATCC;Manassas,
VA, USA) were maintained in RPMI-1640 and DMEM medium, respectively. 10% of fetal
bovine serum (FBS) and 1% antibiotics (penicillin-streptomycin) were supplemented to
the media, then it was incubated under an atmosphere of 5% CO2 and 95% humidified
air at 37 ◦C. The medium was replaced twice weekly until confluent cell monolayer was
formed and observed under an inverted microscope.
Cellular viability assay
The inhibitory effect of methanolic extract of carob was determined by MTT assay. The
reduction of MTT (3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide) by
the mitochondrial dehydrogenase in cells and producing purple formazan is the principle
of the experiment. In which 5 ×103 of WRL 68 and RIN-5F per well were seeded in
triplicate in 96-well microplates and incubated for 24 h to be attached at 37 ◦C with 5%
CO2 saturation. After 24 h of incubation, decreasing concentrations of carob methanolic
extract (such as 1,000, 500, 250, 125, 60, 30, 15 and 7 µmol) were prepared (0.025%
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DMSO) and transferred to the cells with incubating for 24, 48,72 h at 37 ◦C and 5% CO2.
Subsequently, 20 µL of MTT solution (5 mg mL−1) was added to the treated cells in a
dark place, covered with aluminum foil and incubated for 4 h. All media was discharged
and a total of 100 µL of DMSO was poured into each well until the purple formazan
crystals dissolved (Jayash et al., 2016; Jayash et al., 2017). The blank was performed in a
similar manner but the test samples were replaced by media (0.025% DMSO). The plates
were measured using a microplate reader UV-Visible spectrophotometry (Infinite M 200;
Tecan, Switzerland) at absorbance 570 nm. The tests were carried out in 96-well microplates
(Solid clear F-bottom; Greiner Bio One, Kremsmuenster, Austria). All experiments were
conducted in triplicate to evaluate the IC50 (The concentration of the methanolic carob
extract that was able to inhibit 50% of cells viability). The percentage of cell viability was
calculated using the following equation: Cell viability% = A treated cells/A blank ×100.
According to Jayash et al. (2017), the cytotoxic effect of each serial dilution of the
methanolic extract of carob was evaluated.
Acute oral toxicity of the methanolic extract of carob
Acute oral toxicity was conducted according to the guidelines of OECD (OECD, 2005) and
ethical approval (2014-07-01/PHARM/MAQA) that was issued by the Institutional Ethics
Committee, University of Malaya, Malaysia. The animals were kept under the standard
conditions of housing as mentioned above. Totally, 36 adult SD-rats (18 males and 18
females) were randomly dispersed into normal control (n= 6), low dose methanolic carob
extract (CS2000) (n= 6) and high dose methanolic carob extract (CS5000) (n= 6), which
received an oral single dose of 5 mL kg−1 normal saline, 2,000 mg kg−1 carob and 5,000
mg kg−1 carob during the 14 days of the acute oral toxicity time course, respectively.
Experimental rats were fasted overnight before dosing. Immediately after dosing, rats were
observed at half an hour, 2, 4, 24 and 48 h for any toxicological signs. By the 14th day, rats
were fasted overnight, anaesthetized, scarified to collect blood samples via cardiac puncture.
Blood samples were centrifuged at 1,500 rpm to obtain serum to measure liver function
tests, kidney function tests and total protein. as well as liver and kidney were harvested and
their sections were processed to be stained with H&E stain for histopathology evaluation.
In vivo glycaemic activity of the methanolic extract of carob
Experimental animals
Totally, 30 male Sprague–Dawley rats (7–8 weeks) were obtained from the Animal House
Unit (AEU) in the Faculty of Medicine, University of Malaya. Malaysia. Animals were kept
following the Guide for the Care and Use of Laboratory Animals published by (Institute
for Laboratory Animal Research, 2010). The use of animals and the study was conducted
according to the ethic approval issued by Institutional Animal Care and Use Committee
(FOM IACUC), Faculty of Medicine, University of Malay, Malaysia in 18 August 2014
under ethic number (2014-07-01/PHARM/MAQA). The animals were kept within the
AEU at Faculty of Medicine, University of Malaya and allowed to acclimatize for one week
under 20 ± 3 ◦C, relative humidity (30–70%) and 12 h light/dark cycle with free access to
food and water.
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Induction of type 2 diabetic animal model
According to the protocol of (Arya et al., 2012a) , the rats were fasted overnight and injected
with a single intraperitoneal dose of 55 mg kg−1 of freshly prepared streptozotocin (STZ) in
0.1M citrate buffer (pH 4.5). Immediately after 15mins, rats were injected intraperitoneally
with 210 mg kg−1 nicotinamide (NAD) which exert an antioxidant capacity that minimize
the cytotoxic actions of STZ and protects pancreatic β-cell against the destructive effect
of STZ (Furman, 2015). After 96 h, rats were fasted overnight except free access for tap
water to measure fasting blood sugar using Accu-Chek glucometer. The injected rats were
monitored for 10 days and those which attained fasting blood sugar between 10-14 mmol
L−1 were considered type 2 diabetic.
Dose rationale of carob
In this study, the doses of the methanolic carob extract were selected to be 500 mg kg−1 as
a low dose (CS500) and 1,000 mg kg−1 as a high dose (CS1000) according to the pervious
study by Rtibi et al. (2015b).
The experimental design
The type2 induced rats were randomly assigned into four groups (n= 6); namely, diabetic
untreated control (D0), diabetic glibenclamide-treated (GD), diabetic low dose carob-
treated (CS500) and diabetic high dose carob-treated (CS1000), which received a single
oral daily dose of 5 mL kg−1 normal saline, 5 mg kg−1 glibenclamide (Hafizur et al., 2015),
500mg kg−1 carob and 1,000mg kg−1 carob for four weeks respectively. An extra untreated
non-diabetic control (NC) (n= 6) was added and given oral daily single dose of 5 mL kg−1
of normal saline for four weeks. Blood glucose level wasmonitored weekly from the tail vein
using Accu-Chek glucometer. Body weight was recorded at the day of starting (initial body
weight) and cession of treatment (final body weight). By the 28th days of treatment, rats
were anaesthetized using ketamine (50 mg kg−1) and xylazine (5.0 mg kg−1). Then, 5 mL of
blood samples were collected for blood analysis through cardiac puncture. Blood samples
were centrifuged at 2,000 rpm for 10 min and serum samples were separated and stored
at −80 for the future use. Subsequently, rats were scarified by increasing anesthetic dose
(ketamine 150 mg kg−1& xylazine 15.0 mg kg−1) to obtain pancreas for gross pathology
examination.
Oral glucose tolerance test
Oral glucose tolerance test (OGTT) evaluated the glucose challenge ability of each animal
one week prior to animal sacrifice (Arya et al., 2012b). After fasting rats overnight, tip tail
fasting blood glucose was measured at 0 time. Twenty minutes after rats had received their
own treatment, rats were given a single oral dose of glucose solution (3 g/kg), and blood
glucose was measured at 30, 60, 90 and 120 min.
Evaluation of insulin resistance
Aftermeasuring fasting serum insulin, homeostaticmodel assessment (HOMA-IR,HOMA-
β and HOMA-S) was estimated (Mather, 2009). Serum insulin was quantified by the
enzyme-linked immunosorbent assay (ELISA) using an ultrasensitive rat insulin ELISA
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Table 1 Total phenolic and flavonoid with the antioxidant activities of the methanolic extract of Carob. The table demonstrated that the pheno-
lic content (y = 0.0075x−0.0123, R2= 0.9817) was 127.02±7.18 mg GAE g−1, while the flavonoid content (y = 0.0023x−0.0165, R2= 0.9979) was
49.74± 0.88 mg QE g−1, which means that flavonoid content approximately accounted for 39.2% of the total phenolic content.
Total phenolic content
(mg GAE g−1)
Total flavonoid Content
(mg QE g−1)
DPPH radical
IC50: µg mL−1
FRAP assay
µmoL FeSo4 mg−1
Carob extract 127.02± 7.18 49.74± 0.88 11.23± 0.47 3191.67± 54.34
Quercetin – – 6.64± 0.07 6565.17± 678.75
Trolox – – 9.46± 0.14 6433± 216.49
Notes.
Values were expressed as mean ± SE (n= 3).
kit (ER1113, Wuhan Fine Biological Technology Co., Ltd., China) and read at 450 nm
with a microplate reader (Hydroflex Elisa; Chemo pharm, Vienna, Austria) according to
the manufacturer’s instructions. HOMA-IR, HOMA- β and HOMA-S were estimated in
term of fasting insulin (µU mL−1) and fasting blood glucose (mmol L−1) using HOMA 2
calculator software (Diabetes Trial Unit UoO, UK, 2004).
Histopathological examinations
For histological analysis, pancreatic tissues were collected directly after sacrificing
animals and fixed with formaldehyde 10% (v/v). Histopathological examinations were
accomplished by an experienced pathologist. The pancreases sections were stained
with hematoxylin and eosin (H&E). Histological features including morphological
configuration, size of islets and number of β-cells were examined and differentiated
for each group.
Statistical analysis
The statistical analysis was determined using a statistical software package (SPSS for
Windows, version 23, IBM Corporation, Armonk, NY, USA) and analysis of variance
(ANOVA ), followed by Tukey’s-SHD;multiple range post-hoc test. The IC50 was calculated
from the linear regression analysis. Pearson correlation coefficient analysis was done to
evaluate the correlation between phenolic and flavonoid contents against antioxidant
activities. Values were considered statistically significant at P < 0.05. Results were expressed
as either means ± SD or means ± SE.
RESULTS
Antioxidant activity
Table 1 demonstrated that the phenolic content (y = 0.0075x – 0.0123, R2= 0.9817) was
127.02± 7.18mgGAE g−1, while the flavonoid content (y = 0.0023x – 0.0165,R2= 0.9979)
was 49.74± 0.88mgQE g−1, whichmeans that flavonoid content approximately accounted
for 39.2% of the total phenolic content. According to IC50 values, the scavenging activity
of the methanolic extract against the free radicals of DPPH (y = 13.339 ln (x) + 17.685,
R2= 0.9727) was close to that of Trolox, but it was double that of quercetin. Similarly, FRAP
value (y = 0.0002x+0.002, R2= 0.9649) of the methanolic extract was approximately half
that of either quercetin or Trolox.
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Figure 2 Effect of the methanolic extract of carob on viability of pancreatic RIN-5F cells. The percent-
age of viability of RIN-5F cells after 24, 48 and 72 h of exposure to the methanolic extract of carob. The
percentage of viability was upper than 30%. Values were expressed as mean±SD (n= 3).
Full-size DOI: 10.7717/peerj.4788/fig-2
Table 2 Correlation coefficients of phenolic and flavonoid contents against antioxidant assays. The
Pearson correlations analysis displayed that the total phenolic content of carob methanolic extract had a
strong positive correlation with FARP assay (r = 0.918, P < 0.01) and a strong negative with DPPH radi-
cal (r =−0.910, P < 0.01). Likewise, total flavonoid content of carob methanolic extract reflects a strong
positive correlation with FRAP asaay (r = 0.886, P < 0.01) and a strong negative correlation with DPPH
radical (r =−0.867, P < 0.01).
Methanolic carob extract FRAP assay DPPH radical
Total phenolic content 0.918** −0.910**
Total flavonoid content 0.886** −0.867**
Notes.
**means correlation is significant at the 0.01 level (2-tailed).
Pearson correlations analysis displayed that the total phenolic content of carob
methanolic extract had a strong positive correlation with FARP assay (r = 0.918, P < 0.01)
and a strong negative with DPPH radical (r =−0.910, P < 0.01).
Likewise, total flavonoid content of carob methanolic extract reflects a strong positive
correlation with FRAP assay (r = 0.886, P < 0.01) and a strong negative correlation with
DPPH radical (r =−0.867, P < 0.01), (Table 2).
Toxicity assessment of the methanolic extract of carob
In vitro cytotoxicity
In the current study, the toxic effect of the methanolic extract of carob against RIN-5F
(pancreatic β-cells) and WRL 68 (human hepatocytes cells) was assessed. The percentage
of viability of either RIN-5F (Fig. 2) or WRL 68 (Fig. 3) was upper than 30% after 24, 48
and 72 h of exposure to the different serial concentrations of the methanolic extract of
carob.
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Figure 3 Effect of the methanolic extract of carob on viability ofWRL 68 cells. The percentage of viabil-
ity of WRL 68 cells after 24, 48 and 72 h of exposure to the methanolic extract of carob. The percentage of
viability was upper than 30%. Values were expressed as mean±SD (n= 3).
Full-size DOI: 10.7717/peerj.4788/fig-3
Table 3 Body weight as well as absolute and relative organ weight of female andmale rats.No significant difference was observed in body weight
of male and female rats. Like body weight, absolute liver, kidney, heart and pancreas weights, as well as relative liver, kidney, heart and pancreas
weights of male and female rats were not significantly different.
Females Males
NC CS2000 CS5000 NC CS2000 CS5000
BW0 230.00± 15.16 226.67± 18.61 230.83± 13.93 356.67± 22.73 363.33± 39.33 360.83± 36.66
BW1 246.33± 16.08 251.67± 24.83 260.83± 14.63 410.00± 24.70 407.50± 41.32 402.50± 37.52
BW2 250.00± 20.73 244.17± 21.77 237.50± 15.73 399.17± 25.3 406.67± 39.96 391.67± 40.21
ALW 7.88± 0.75 7.53± 0.86 7.40± 1.12 12.70± 0.83 12.23± 1.72 12.2± 1.1
AKW 1.78± 0.25 1.55± 0.19 1.65± 0.19 2.77± 0.23 2.65± 0.31 2.70± 0.36
AHW 0.85± 0.15 0.85± 0.10 0.80± 0.09 1.13± 0.16 1.35± 0.19 1.22± 0.15
APW 1.22± 0.15 1.15± 0.19 1.05± 0.24 1.47± 0.29 2.00± 0.59 1.78± 0.50
RLW 0.032± 0.001 0.031± 0.002 0.031± 0.003 0.032± 0.002 0.030± 0.002 0.031± 0.001
RKW 0.007± 0.001 0.006± 0.0003 0.007± 0.001 0.007± 0.001 0.007± 0.0003 0.007± 0.0004
RHW 0.003± 0.0005 0.004± 0.0003 0.003± 0.0003 0.003± 0.0004 0.003± 0.0003 0.003± 0.0002
RPW 0.005± 0.0003 0.005± 0.0005 0.004± 0.0007 0.004± 0.001 0.005± 0.001 0.004± 0.001
Notes.
NC, normal control; CS2000, 2,000 mg kg−1 carob-treated; CS5000, 5,000 mg kg−1 carob-treated; BW0, 1 and 2, body weight before treatment as well as at the end of 1st and
2nd week of treatment, respectively; ALW, absolute liver weight; AKW, absolute kidney weight; AHW, absolute heart weight; APW, absolute pancreas weight; RLW, rela-
tive liver weight; RKW, relative kidney weight; RHW, relative heart weight; RPW, relative pancreas weight. Values are expressed as mean ±SD, (n= 6).
In vivo acute oral toxicity
Neithermorbidity normortality inmale or female ratswas observed. Similarly, no abnormal
signs or behavioral changes were observed during the course of acute oral toxicity. Table 3
showed that no significant difference was observed in body weight of male and female rats.
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Table 4 Biochemical parameters for male and female rats.Only alkaline phosphatase and urea of CS5000 were significantly increased as com-
pared to normal control (NC). In female rats, only serum creatinine showed significant increased as compared to noramal control.
Females Males
NC CS2000 CS5000 NC CS2000 CS5000
ALP 73.60± 3.21 76.20± 20.99 93.60± 16.13 76.80± 11.97 79.00± 12.25 142.00± 7.87**
AST 93.80± 10.03 126.80± 32.58 132.60± 38.49 101.60± 13.46 121.20± 14.57 100.60± 25.77
ALT 59.80± 4.82 53.20± 11.90 57.80± 1.64 34.00± 4.74 34.80± 3.77 40.20± 5.93
TP 30.00± 1.87 31.60± 7.02 35.20± 2.86 7.26± 0.42 7.28± 0.38 7.06± 0.46
Cr 6.12± 0.52 7.36± 1.68 9.62± 1.93** 51.80± 6.98 53.20± 2.68 52.00± 2.55
Ur 7.58± 0.26 7.58± 0.57 7.00± 0.53 7.06± 1.21 7.36± 1.07 11.20± 1.18*
Notes.
NC, normal control; CS2000, 2,000 mg kg−1 carob-treated; CS5000, 5,000 mg kg−1 carob-treated; ALP, alkaline phosphatase; AST, aspartate aminotransferase; ALT, alanine
aminotransferase; TB, total bilirubin; Cr, creatinine; Ur, urea.
*, **symbolized a significant difference at either P < 0.05 or P ≤ 0.01 versus normal control. Values were expressed as mean±SD, (n= 5).
Like body weight, absolute liver, kidney, heart and pancreas weights, as well as relative
liver, kidney, heart and pancreas weights of male and female rats were non-significantly
different. Table 4 showed that only alkaline phosphatase and urea of high dose carob-treated
(CS5000) were significantly increased as compared to normal control (NC) (P ≤ 0.05 and
P ≤ 0.01, respectively). In female rats, only serum creatinine showed significant increased
as compared to normal control (P ≤ 0.01).
Histopathology of acute oral toxicity
The liver histological sections of normal control (G and J), low dose carob-treated CS2000
(H and K) and high dose carob-treated CS5000 (I and L) of both male and female were
of normal architecture of hepatocytes at the level of their cell membrane, nuclei or even
cytoplasm. In addition, no congestion in portal veins, no necrotic lesions, no inflammatory
signs or fatty infiltrations could be observed. Similarly, kidney histological sections of
normal control (A andD), CS2000 (B and E) andCS5000 (C and F) of bothmale and female
were of normal architecture of tubules, Bowman’s capsule, Malpighian corpuscles (Fig. 4).
Glycemic effect of the methanolic extract of carob
In vitro glycemic effect
The IC50 of carob methanolic extract (92.99 ± 0.22 µg mL−1) was higher than that of
α-acarbose (23.33 ± 0.73 µg mL−1) against α-amylase (Fig. 5). Similarly, the IC50 of the
methanolic extract (97.13 ± 4.11 µg mL−1) against α-glucosidase was higher than that of
α-acarbose (27.05 ± 0.99 µg mL−1) (Fig. 6).
In vivo glycemic effect
Body weights as well as absolute and relative organs weight of STZ-NAD
diabetic animal model
Table 5 demonstrates that body weight of low dose carob-treated (CS500) and high dose
carob-treated (CS1000) was significantly reduced more than untreated type 2 diabetic rats
(D0) (P ≤ 0.05 and P ≤ 0.01, respectively). On the other hand, absolute pancreas weight
(APW) and relative pancreas weight (RPW) of CS1000 were significantly lower than that
of untreated type 2 diabetic rats group (P ≤ 0.001 and P ≤ 0.01, respectively).
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Figure 4 Hematoxylin and eosin stained histopathological sections of livers and kidneys of male and
female SD-rats. The hematoxylin and eosin stained histopathological sections of livers and kidneys of
male and female SD-rats. (A–C) normal control (NC): 2,000 mg kg−1 carob-treated (CS2000) and 5,000
mg kg−1 carob-treated (CS5000) male kidney sections, respectively. (D–F) normal control (NC): 2,000
mg kg−1 carob-treated (CS2000) and 5,000 mg kg−1 carob-treated (CS5000) female kidney sections,
respectively. (G–I) normal control (NC): 2,000 mg kg−1 carob-treated (CS2000) and 5,000 mg kg−1
carob-treated (CS5000) male liver sections, respectively. (J–L) normal control (NC): 2,000 mg kg−1
carob-treated (CS2000) and 5,000 mg kg −1 carob-treated (CS5000) female liver sections, respectively.
Liver sections of (G–L) showed similar normal architecture of hepatocytes at the level of their cell
membrane, nuclei or even cytoplasm without any abnormalities such as congestion of portal veins,
necrotic lesions, inflammatory signs or fatty infiltrations. Similarly, kidney sections of all groups similar
normal architecture of tubules, Bowman’s capsule, Malpighian corpuscles without any abnormal findings
(magnification× 40).
Full-size DOI: 10.7717/peerj.4788/fig-4
Weekly fasting blood sugar of STZ-NAD diabetic animal model
Figure 7 showed that normal control (NC) showed a higher significant fasting blood
glucose (FBG) than untreated type 2 diabetic rats (D0) at the baseline as well as the end of
the 1st, 2nd, 3rd and 4th week of treatment (P ≤ 0.001, P ≤ 0.001, P ≤ 0.001, P ≤ 0.001
Qasem et al. (2018), PeerJ, DOI 10.7717/peerj.4788 13/27
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Figure 5 Inhibitory effect of the methanolic extract of carob against α-amylase. The percentage of
inhibition of the methanolic carob extract and α-acarbose against against α-amylase. The IC50 of carob
methanolic extract (92.99± 0.22 µg mL−1) was higher than that of α-acarbose (23.33± 0.73 µg mL−1)
against α-amylase.
Full-size DOI: 10.7717/peerj.4788/fig-5
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Figure 6 Inhibitory effect of the methanolic extract of carob against α-glucosidase. The percentage of
inhibition of the methanolic carob extract and α-acarbose against α-glucosidase. The IC50 of the methano-
lic carob extract (97.13± 4.11 µg mL−1) against α-glucosidase was higher than that of α-acarbose (27.05
± 0.99 µg mL−1).
Full-size DOI: 10.7717/peerj.4788/fig-6
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Table 5 Body weight as well as absolute and relative pancreas weight of STZ-NAD diabetic animal model. The table demonstrated that body
weight of CS500 and CS1000 was significantly reduced more than untreated type 2 diabetic rats (D0). On the other hand, absolute pancreas weight
(APW) and relative pancreas weight (RPW) of CS1000 were significantly lower than that of untreated type 2 diabetic rat group.
NC D0 GD CS500 CS1000
BW0 287.2± 32.31 289.2± 17.42 282.3± 22.84 273.3± 16.33 288.7± 20.71
BW4 360.3± 30.92 333.7± 14.53 306.0± 8.31 296.8± 13.82* 281.3± 25.02**
APW 2.34± 0.16 2.02± 0.33 1.79± 0.14 1.62± 0.36 1.27± 0.37***
RPW 0.0066± 0.001 0.0063± 0.001 0.0059± 0.001 0.0055± 0.001 0.0044± 0.001**
Notes.
NC, normoglycemic untreated rats; D0, untreated type 2 diabetic rats; GD, glibenclamide-treated type 2 diabetic; CS500, 500 mg kg−1 of carob-treated type 2 diabetic; CS1000,
1,000 mg kg −1 of carob-treated type 2 diabetic; BW0 and 4, initial body and final body weight, respectively; APW, absolute pancreas weight; RPW, relative pancreas weight.
*, ***, ***denoted a significant difference at P ≤ 0.05, P ≤ 0.01 and P ≤ 0.001 versus D0. Values were expressed as mean±SE, (n= 6).
and P ≤ 0.001, respectively). In addition, FBG of glibenclamide-treated type 2 diabetic
(GD) was significantly lower than untreated type 2 diabetic rats at the end of the 2nd, 3rd,
and 4th weeks (P ≤ 0.001, P ≤ 0.001 and P ≤ 0.001, respectively). Moreover, low dose
carob-treated (CS500) showed a lower significant FBG than untreated type 2 diabetic rats
only at the end of 4th week (P ≤ 0.001) while high dose carob-treated (CS1000) exhibited
a lower significant FBG than untreated type 2 diabetic rats at the end of 3rd and 4th weeks
(P ≤ 0.01 and P ≤ 0.001, respectively).
Oral glucose tolerance test (OGTT)
Figure 8 illustrates that blood glucose of untreated type 2 diabetic (D0) was significantly
higher than that of normal control (NC) at zero (P ≤ 0.01), 30 (P ≤ 0.001), 60 (P ≤ 0.001),
90 (P ≤ 0.001) and 120 (P ≤ 0.001). Conversely, blood glucose of glibenclamide-treated
type 2 diabetic (GD) was significantly lower than that of untreated type 2 diabetic at 30
(P ≤ 0.05), 60 (P ≤ 0.001), 90 (P ≤ 0.001) and 120 (P ≤ 0.001). However, blood glucose
of low dose carob-treated (CS500) and high dose carob-treated (CS1000) was significantly
lower than that of untreated type 2 diabetic at 90 (P ≤ 0.01 and P ≤ 0.001, respectively)
and 120 min (P ≤ 0.001 and P ≤ 0.001, respectively).
Biochemistry and hemostatic assessment index of STZ-NAD diabetic
animal model
Table 6 showed that total protein of glibenclamide-treated type 2 diabetic (GD) and
high dose carob-treated (CS1000) was significantly higher than that of untreated type 2
diabetic (D0) (P ≤ 0.01 and P ≤ 0.01, respectively). On the other hand, serum amylase
of untreated type 2 diabetic was significantly lower than that of normal control (NC)
(P ≤ 0.001), glibenclamide-treated type 2 diabetic ( P ≤ 0.001), low dose carob-treated
(CS500) (P ≤ 0.001) and high dose carob-treated (P ≤ 0.001). Serum FBG of untreated
type 2 diabetic was higher than that of normal control (P ≤ 0.001), while serum FBG of
glibenclamide-treated type 2 diabetic and high dose carob-treated was significantly lower
than that of untreated type 2 diabetic (P ≤ 0.001 and P ≤ 0.001, respectively). However,
only insulin of untreated type 2 diabetic was less than that of normal control (P ≤ 0.001).
In addition, HOMA-B of untreated type 2 diabetic was significantly less than that of
normal control (P ≤ 0.001), glibenclamide-treated type 2 diabetic (P ≤ 0.001), low dose
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Figure 7 Weekly fasting blood glucose of STZ-NAD diabetic animal model. The fasting blood glucose
(FBG) of normal control group (NC) was higher significant than untreated type 2 diabetic rats (D0)
at the baseline as well as the end of the 1st, 2nd, 3rd and 4th week of treatment. In addition, FBG of
glibenclamide-treated type 2 diabetic (GD) was significantly lower than D0 at the end of the 2nd, 3rd, and
4th weeks. Moreover, CS500 showed a lower significant FBG than D0 only at the end of 4th week while
CS1000 exhibited a lower significant FBG than D0 at the end of 3rd and 4th weeks. NC: normoglycemic
untreated rats, D0: untreated type 2 diabetic, GD: glibenclamide-treated type 2 diabetic, CS500: 500 mg
kg−1 of carob-treated type 2 diabetic, CS1000: 1,000 mg kg−1 of carob-treated type 2 diabetic. FBG_0,
1, 2, 3 and 4: fasting blood glucose at baseline as well as at the end of the 1st, 2nd, 3rd and 4th week of
treatment, respectively. Superscript ###: denoted a significant difference at P ≤ 0.001 versus normal
control. Superscript **, ***: denoted a significant difference at P ≤ 0.01 and P ≤ 0.001 versus D0. Values
were expressed as mean±SE, (n= 6).
Full-size DOI: 10.7717/peerj.4788/fig-7
carob-treated (P ≤ 0.05) and high dose carob-treated (P ≤ 0.01), while HOMA-S and
HOMA-IR showed a non-significant difference.
Histopathology of STZ-NAD diabetic animal model
Figure 9 showed that histological examination of pancreatic tissues exhibited that
normoglycemic untreated rats (A) showed a normal tissue morphological configuration
and a larger islet (indicated by red arrow) with high number of β-cells (indicated by
yellow arrow), while the untreated type 2 diabetic (B) had the smallest islet and structural
malformation with lowest number of β-cells. The high dose carob-treated (E), low dose
carob-treated (D) and glibenclamide-treated type 2 diabetic (C) groups had comparatively
larger islets with some abnormal structure and higher numbers of β-cells were observed as
compared to the untreated type 2 diabetic rats (B).
DISCUSSION
The extraction solvents play a vital role in the pharmacological activities (Turkmen, Sari &
Velioglu, 2006) since the content of an extract is almost dependent on the extraction solvent,
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Figure 8 Oral glucose tolerance test of STZ-NAD diabetic animal model. The blood glucose of un-
treated type 2 diabetic rats (D0) was significantly higher than that of normal control (NC) at zero, 30, 60,
90 and 120. Conversely, blood glucose of glibenclamide-treated type 2 diabetic (GD) was significantly
lower than that of untreated type 2 diabetic at 30, 60, 90 and 120. However, blood glucose of CS500 and
CS1000 was significantly lower than that of untreated type 2 diabetic at 90 and 120 minutes. NC: normo-
glycemic untreated rats, D0: untreated type 2 diabetic, GD: glibenclamide-treated type 2 diabetic, CS500:
mg kg−1 of carob-treated type 2 diabetic, CS1000:1000 mg kg−1 of carob-treated type 2 diabetic. Super-
script ##, ###: denoted a significant difference at P ≤ 0.01 and P ≤ 0.001 versus normal control. Super-
script *, **, ***: denoted a significant difference at P ≤ 0.05, P ≤ 0.01 and P ≤ 0.001 versus D0. Values
were expressed as mean±SE, (n= 6).
Full-size DOI: 10.7717/peerj.4788/fig-8
therefore, the current study used methanol as a solvent of extraction for carob because it
is one of the universal solvents which is capable of extracting non- polar, semi-polar and
polar constituents (Saghir et al., 2016).
Earlier reports indicated that carob pods contain considerable amounts of phenolic
compounds such as tannins (proanthocyanidins, gallotannins and ellagitannins),
flavonoids, gallic acid, (+)-catechin, (−)-epigallocatechin gallate, cinnamic acid, p-
coumaric acid and quercetin glycosides (Gulay et al., 2012;Marakis, 1996;Owen et al., 2003;
Rtibi et al., 2017a). Our findings revealed that the methanolic extract of carob had a high
content of total phenolic and flavonoids. In the current study, the antioxidant activity of the
methanolic carob extract using DPPH and FRAP assays was evaluated prior to conduct its
in vivo antioxidant activity to provide a preliminary evidence about the antioxidant activity
of the Yemeni cultivar of carob which has not been yet reported. Actually, our findings
of in vitro antioxidant activity indicated that the methanolic extract of carob produced a
scavenging activity against free radicals of DPPH which was higher than that was reported
by Rtibi et al. (2017b). Likewise, the methanolic extract of carob exhibited a ferric reducing
antioxidant power that accounted for 50% of those exhibited by quercetin and Trolox.
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Table 6 Biochemistry and hemostatic assessment index of STZ-NAD diabetic animal model. The total protein of glibenclamide-treated type 2
diabetic (GD) and CS1000 was significantly higher than that of untreated type 2 diabetic (D0). On the other hand, serum amylase of untreated type
2 diabetic was significantly lower than that of normal control, glibenclamide-treated type 2 diabetic, CS500 and CS1000. Serum FBG of untreated
type 2 diabetic was higher than that of normal control (NC), while serum FBG of glibenclamide-treated type 2 diabetic and CS1000 was significantly
lower than that of untreated type 2 diabetic. However, only insulin of untreated type 2 diabetic was less than that of normal control. In addition,
HOMA-B of untreated type 2 diabetic was significantly less than that of normal control, glibenclamide-treated type 2 diabetic, CS500 and CS1000,
while HOMA-S and HOMA-IR showed a non-significant difference.
NC D0 GD CS500 CS1000
TP g L−1 90.60± 6.40 77.10± 12.71 100.52± 7.06** 86.68± 10.37 101.16± 8.65*
Amy U L−1 2,891.80± 22.1 1,717.00 ± 24.81### 2,757.60± 18.91*** 2,863.00± 21.20*** 2,910.60± 22.42***
TG mmol L−1 0.52± 0.24 0.63± 0.41 0.81± 0.27 0.77± 0.24 0.84± 0.32
TC mmol L−1 2.70± 0.24 2.52± 1.07 3.16± 0.30 2.82± 0.49 3.36± 0.69
FBG mmol L−1 4.90± 0.41 13.51 ± 1.23### 6.50± 0.40*** 12.34± 0.90 10.35± 0.85***
IN mU L−1 15.55± 1.26 10.60 ± 0.95### 13.15± 2.22 11.26± 1.25 12.44± 1.87
HOMA- β 163.28± 24.46 17.43 ± 0.93### 82.48± 12.41*** 22.85± 2.95* 33.88± 7.39**
HOMA-S 51.12± 4.32 55.73± 5.89 56.80± 8.33 56.43± 7.42 54.03± 7.49
HOMA-IR 1.97± 0.19 1.78± 0.22 1.80± 0.31 1.80± 0.23 1.88± 0.26
Notes.
NC, normoglycemic untreated rats; D0, untreated type 2 diabetic; GD, glibenclamide-treated type 2 diabetic; CS500, 500 mg kg−1 of carob-treated type 2 diabetic; CS1000,
1,000 mg kg−1 of carob-treated type 2 diabetic; TP, total protein; Amy, amylase; FBG, fasting blood glucose; IN, insulin; HOMA- β, β eta cell function; HOMA-S, insulin
sensitivity; HOMA-IR, insulin resistance.
###denoted a significant difference at P ≤ 0.001 versus normal control.
*, **, ***denoted a significant difference at P ≤ 0.05, P ≤ 0.01 and P ≤ 0.001 versus D0. Values were expressed as mean±SD, (n= 6).
The antioxidant properties of the methanolic extract of carob maybe act through its
ability to neutralize reactive oxygen species and myeloperoxidase (Rtibi et al., 2017a; Rtibi
et al., 2017b). Nonetheless, the in vitro and in vivo antioxidant activity for most plants was
not always the same (Kasote et al., 2015). Accordingly, further studies should consider the
effect of methanolic extract of carob on the in vivo antioxidant enzymatic system using
pancreatic homogenate.
Universally, natural products are considered as one of the most common source of drugs
(Newman, Cragg & Snader, 2003). Regardless of the effectiveness of natural products, those
products should firstly be assessed for their safety (Evans et al., 2001; Mounanga, Mewono
& Angone, 2015). In the present study, the safety of the methanolic extract of carob was
assessed in vitro on pancreatic β-cells and hepatocytes followed by in vivo assessment of its
acute toxicity on male and female rats for 14 days. Accordingly, our findings indicated that
the methanolic extract of carob was not toxic against pancreatic β cells and hepatocytes as
long as the viability of both cells remained more than 30% after 24, 48 and 72 h of exposure
to carob (Jayash et al., 2017). Although in vivo acute oral toxicity findings indicated a rise
in ALP and urea of male rats as well as creatinine of female rats. As it is known that liver is
the main site of biotransformation of xenobiotics into metabolites which could sometimes
be hepatotoxic (Sturgill & Lambert, 1997) inducing a rise in hepatic biomarkers (ALP, AST
and ALT) and histological abnormalities through destructing cell membrane and structures
of hepatocytes (Apaydin et al., 2017). However, ALP is ubiquitous in several body organs
and has several isoenzymes (Moss, 1982). Accordingly, the increase in ALP of male rats
could be extrahepatic. Regarding the increase in creatinine of female rats, it is well-known
that creatinine is a measure of kidney functions, however, it was reported that creatinine is
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Figure 9 Hematoxylin and eosin stained nicotinamide streptozotocin-induced diabetic rats. The his-
tological examination of pancreatic tissues exhibited that normoglycemic untreated rats (A) showed a nor-
mal tissue morphological configuration and a larger islet (indicated by red arrow) with high number of β-
cells (indicated by yellow arrow), while the untreated type 2 diabetic (B) had the smallest islet and struc-
tural malformation with lowest number of β-cells. In addition, high dose carob-treated type 2 diabetic
CS1000 (E), low dose carob-treated type 2 diabetic CS500 (D) and glibenclamide-treated type 2 diabetic
(C) had comparatively larger islets with some abnormal structure and higher numbers of β-cells were ob-
served as compared to the untreated type 2 diabetic (B). (A) normoglycemic untreated rats (NC), (B) un-
treated type 2 diabetic (D0), (C) glibenclamide-treated type 2 diabetic (GD), (D) 500 mg kg−1 of carob-
treated type 2 diabetic (CS500), (E):1,000 mg kg−1 of carob-treated type 2 diabetic (CS1000). Red and yel-
low arrows denoted to pancreatic islets and β-cells, respectively (magnification×40).
Full-size DOI: 10.7717/peerj.4788/fig-9
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no longer imprecise biomarker (Inker et al., 2012). Consequently, this study relied on the
histological findings in livers and kidneys sections of male and female rats to detect any
direct toxicity evidence due to the exposure to carob. Actaully, the hsitological sections of
liver of male and female rats showed normal architecture of hepatocytes (at the level of
their cell membrane, nuclei or even cytoplasm), without necrotic lesions, inflammatory
signs or fatty infiltrations. Similarly, histological sections of kidneys of male and female
rats showed normal architecture of tubules, Bowman’s capsule, Malpighian corpuscles.
Carob as a plant bears a great significance in the traditional medicine because of
its various pharmacological activities (Gulay et al., 2012; Rtibi et al., 2017a). Interesetingly,
carob is a native plant to Yemen and it is used as a traditional medicine to improve glycemic
control in diabetics long time ago (Battle & Tous, 1997; Papakonstantinou et al., 2017). In
point of fact, the previous reports suggested that the physiological viscous property of
soluble fiber of carob pods gum could modify carbohydrates structure during digestion
which can modify the rate of carbohydrate degradation and control blood glucose levels
(Barak & Mudgil, 2014; Forestieri et al., 1989; Marles & Farnsworth, 1995). Consequently,
this drew our attention to examine the in vitro inhibitory effect of carob against α-amylase
and α-glucosidase which are responsible for post-prandial conversion of carbohydrates
into glucose units (Etxeberria et al., 2012). Accordingly, to assess the glycemic activity of
the methanolic extract of carob, its in vitro glycemic activity was evaluated in term of its
inhibitory effect on α-amylase and α-glucosidase (Etxeberria et al., 2012). Our findings
indicated that carob could inhibit those enzymes, however, its IC50 against both enzymes
was higher than that of α-acarbose indicating that carob has in vitro hypoglycemic activity
but it was not so effective as α-acarbose. On the other hand, the in vivo glycemic activity
of such extract was assessed in T2D animal model. Actually, SD-rats were selected to
create a type 2 diabetic animal model (T2D) since those rats are most commonly used to
investigate the glycemic effects of medicinal plants (Furman, 2015). In addition, SD-rats
are more susceptible to become diabetic with small dose of streptozotocin (STZ), and
its ability to produce a dose-dependent destruction to pancreatic β-cells (Abeeleh et al.,
2009; Furman, 2015). Nevertheless, several protocols have been adopted to induce type 2
diabetes mellitus (T2DM). In this study, animals were injected with intraperitoneal dose
of 55 mg kg−1 of STZ followed by an intraperitoneal dose of 210 mg kg−1 of nicotinamide,
which prevented STZ from producing a complete destruction of pancreatic β-cells in order
to create T2D animal model of relative insulin secretion (Furman, 2015). Our findings
indicated that STZ-NAD induced rats showed FBG of 12.74 ± 0.99 mmol L−1that fall
within the proposed range of FBG of T2DM (7.2–15.6 mmol L−1) (Furman, 2015; Zhang
et al., 2009). Such level of FBG was maintained through the time course of treatment
indicating that the created T2D animal model was stable.
Blood glucose of T2D rats after oral glucose challenge indicated that both low dose
carob-treated (CS500) and high dose carob-treated (CS1000) showed an antihyperglycemic
effect after 90 and 120 min. However, only high dose carob-treated exerted a significant
reduction in FBG at the end of the 3rd and 4th week of treatment, which was emphasized
by the significant increase of total protein of high dose carob-treated due to alleviating the
catabolic effect of the persistent hyperglycemia on proteins (Ng, Ton & Kadir, 2016), and
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the significant reduction in body weigh as a sign of the resulted hypoglycemia (Pandit,
Phadke & Jagtap, 2010). The resulted hypoglycemic effect of high dose carob-treated might
be due to the low GIT value of carob and its high content of fibers which provoked feeling
of satiety (Papakonstantinou et al., 2017) or the polyphenols content of carob could chelate
sugars, lipids and fibers leading to reducing their intestinal absorption (Lattimer & Haub,
2010;Williamson, 2013).
In normoglycemic control rats, the insulin level was significantly higher than that of
untreated type 2 diabetic group (D0). Conversely, the insulin level of all treated and
untreated diabetic rats was non-significantly different, although it was suggested that carob
could enhance insulin release (Forestieri et al., 1989;Marles & Farnsworth, 1995). For other
in vivo mechanisms and pathways, our study recommended further investigation on the
effect of carob on GLP-1. On the other hand, HOMA-B, as surrogate of pancreatic β-cells
activity (Wallace, Levy & Matthews, 2004) was significantly higher than that of untreated
type 2 diabetic due to that normoglycemic rats still had intact pancreatic β-cells since they
were not exposed to the destructive effect of streptozotocin (Furman, 2015), which was
emphasized with their normal findings of the pancreatic histological sections. Similarly,
HOMA-S and HOMA-IR of all treated and untreated diabetic rats as well as normal control
showed a non-significant difference. Actually, the carob pod is rich in D-pinitol compound
(Tetik et al., 2011) which could play an insulin-like role in improving the insulin sensitivity
(Gao et al., 2015). Nonetheless, the used model was streptozotocin-nicotinamide diabetes
induced (insulin deficient model) rather than insulin resistant induced model (Furman,
2015). On the other hand, the slight increase of insulin in of glibenclamide-treated type 2
diabetic (GD) group was due to that glibenclamide is a well-known insulin tropic agent
(Chan & Colagiuri, 2015), while the slight increase in insulin of high dose carob-treated
(CS1000) could be independent of insulin (Papakonstantinou et al., 2017). Perhaps carob
provided a protection to the remaining β-cell from destruction owing to its antioxidant
activity (Coskun et al., 2005; Kaneto et al., 1999; Nasri et al., 2015) particularly that our
findings of the scavenging activity of carob against free radicals of DPPH was indicated.
As mentioned above, however, the findings of the in vitro antioxidant activity of carob
extract could not be extrapolated to reflect the in vivo antioxidant activity (Kasote et al.,
2015). Nonetheless, low dose carob-treated and high dose carob-treated showed a higher
significant value of HOMA-B than that of untreated type 2 diabetic (D0) indicating that
low dose carob-treated (CS500) and high dose carob-treated (CS1000) still had active
insulin secreting β-cells, which could be supported by higher number of β-cells that was
observed in the histological pancreatic sections of low dose carob-treated (D) and high
dose carob-treated (E) as compared to untreated type 2 diabetic (B).
CONCLUSION
Carob pods did not cause acute systemic toxicity and showed in vitro antioxidant effects.
On the other hand, the in vitro ex-pancreatic hypoglycemic effect of the methanolic extract
of carob pods was evident through inhibiting α-amylase and α-glucosidase. Interestingly,
a high dosage of carob exhibits in vivo antihyperglycemic activity and warrants further
Qasem et al. (2018), PeerJ, DOI 10.7717/peerj.4788 21/27
in-depth study to identify the bioactive constituents in the potential methanolic extract of
carob pods.
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